EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS. The post The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings appeared first on Investor's Business Daily.
GSK to explore cancer vaccines with Oxford University in £50mln deal
GSK PLC has unveiled plans to pour £50 million into research with Oxford University over vaccines to prevent some types of cancer. A GSK-Oxford Cancer Immuno-Prevention Programme would investigate how pre-cancerous cells develop, the FTSE 100 pharmaceutical said.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM.
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
GSK plc (NYSE:GSK ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer David Redfern - President Corporate Development Conference Call Participants James Gordon - JPMorgan James Gordon Good morning.
GSK CEO on acquisition of biotech firm IDRx
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
GSK swoops for US cancer specialist in $1.15bn deal
GSK PLC (LSE:GSK, NYSE:GSK) has announced plans to acquire the US biotech company IDRx for up to $1.15bn, including $1bn upfront, in a bid to expand its portfolio of cancer therapies. The deal includes IDRX-42, a promising drug designed to treat gastrointestinal stromal tumours (GIST), a rare and aggressive form of cancer that develops in the digestive tract.
GSK to buy US biotech firm IDRx for up to $1.15 billion
British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.
GSK's new shingles jab submitted for review by US regulator
GSK PLC (LSE:GSK, NYSE:GSK) has announced that the US Food and Drug Administration (FDA) is reviewing its new prefilled syringe version of Shingrix, its shingles vaccine. If approved, the updated delivery method would simplify vaccine administration by eliminating the need to mix separate components before use.
